A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Pyrroles

abstract

  • Obatoclax mesylate added to topotecan does not exceed the historic response rate seen with topotecan alone in patients with relapsed SCLC following the first-line platinum-based therapy.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3715068

Digital Object Identifier (DOI)

  • 10.1016/j.lungcan.2011.05.005

PubMed ID

  • 21620511

Additional Document Info

start page

  • 481

end page

  • 5

volume

  • 74

number

  • 3